China plant expansion bites ShangPharma; UCB selling Indian plant; India mulls new EU API rule;

> Belgium-based UCB is selling a plant in Vapi, India, to Indian API maker Exemed Pharmaceuticals for an undisclosed amount. Story

> The Pharmaceuticals Export Promotion Council of India (Pharmexcil) said while it is considering how to address the 2013 requirement by the EU that all APIs must come from plants that the home country has inspected and certified, the government has yet to finalize how that will be accomplished. Item

> Chinese CRO ShangPharma blamed a nearly 40% drop in net income on the cost of new plants, many of which are yet to come online and start generating revenue, including a new manufacturing plant in Fengxian, China. Story

> German CureVac has developed an RNA vaccine that can be used to manufacture a flu vaccine faster than egg-derived vaccine and will not require cold-chain delivery. Story

> Two class 10,000 clean room facilities are part of the manufacturing upgrades made by Israel's Immunovative Therapies in anticipation of more demand. Item

And Finally... Schott Pharmaceutical Packaging says it will bump up capacity at its plant in Zavolzhe, Russia, by more than 50%. Item

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.